Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
T
TLSI
vs
S&P 500
S&P 500
Over the past 12 months, TLSI has underperformed S&P 500, delivering a return of -10% compared to S&P 500's +16% growth.
Stocks Performance
TLSI vs S&P 500
Performance Gap
TLSI vs S&P 500
Performance By Year
TLSI vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
TriSalus Life Sciences Inc
Glance View
TriSalus Life Sciences makes oncology tools that help doctors deliver cancer drugs more directly to tumors, especially in hard-to-reach areas like the liver and pancreas. Its main product is a pressure-enabled drug delivery system that uses a catheter and infusion platform to push treatment into tumor tissue more effectively than a standard IV drip. The company also works with drug developers and cancer centers to support the clinical use of this delivery approach. Its customers are hospitals, interventional radiologists, oncologists, and pharmaceutical partners that need a better way to get medicines into solid tumors. TriSalus makes money by selling its medical devices and related disposables, and by collaborating with drug companies that want to pair their therapies with its delivery technology. In other words, it sits at the intersection of medical devices and cancer treatment. What makes the business different is that it is not trying to discover new cancer drugs on its own. Instead, it focuses on the delivery problem: getting existing or partnered therapies where they need to go inside the body. That gives the company a specialized role in the cancer care chain, where the value comes from making treatments easier to place, easier to combine, and potentially more effective in tumors that are difficult to treat.